Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line

Proteome Science

Volumn 11, Issue 1, 2013, Pages

  Niu, Meizhi ^a   Klingler Hoffmann, Manuela ^a   Brazzatti, Julie A ^a,c   Forbes, Briony ^a   Akekawatchai, Chareeporn ^a,b   Hoffmann, Peter ^a   McColl, Shaun R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b THAMMASAT UNIVERSITY   (Thailand)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

2D DIGE; Cell migration; CXCR4; EEF2; IGF I; PI3K ; Receptor transactivation

Indexed keywords

ELONGATION FACTOR 2; EUKARYOTIC ELONGATION FACTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; MASS SPECTROMETRY; PHARMACOLOGICAL BLOCKING; PROTEIN PHOSPHORYLATION; PROTEOMICS; RNA INTERFERENCE; TRANSACTIVATION; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EUKARYOTA;

EID: 84872126340     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-11-4     Document Type: Article

References (39)

1. Schafer B, Gschwind A, Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004, 23:991-999. 10.1038/sj.onc.1207278, 14647423.
2. Akekawatchai C, Holland JD, Kochetkova M, Wallace JC, McColl SR. Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J Biol Chem 2005, 280:39701-39708. 10.1074/jbc.M509829200, 16172123.
3. Holland JD, Kochetkova M, Akekawatchai C, Dottore M, Lopez A, McColl SR. Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. Cancer Res 2006, 66:4117-4124. 10.1158/0008-5472.CAN-05-1631, 16618732.
4. Procko E, McColl SR. Leukocytes on the move with phosphoinositide 3-kinase and its downstream effectors. Bioessays 2005, 27:153-163. 10.1002/bies.20157, 15666353.
5. Kundra V, Escobedo JA, Kazlauskas A, Kim HK, Rhee SG, Williams LT, Zetter BR. Regulation of chemotaxis by the platelet-derived growth factor receptor-beta. Nature 1994, 367:474-476. 10.1038/367474a0, 8107807.
6. Radhakrishnan Y, Maile LA, Ling Y, Graves LM, Clemmons DR. Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells. J Biol Chem 2008, 283:16320-16331. 10.1074/jbc.M801687200, 2423238, 18420583.
7. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657. 10.1126/science.296.5573.1655, 12040186.
8. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001, 17:615-675. 10.1146/annurev.cellbio.17.1.615, 11687500.
9. Saudemont A, Garcon F, Yadi H, Roche-Molina M, Kim N, Segonds-Pichon A, Martin-Fontecha A, Okkenhaug K, Colucci F. p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease. Proc Natl Acad Sci USA 2009, 106:5795-5800. 10.1073/pnas.0808594106, 2667007, 19297623.
10. Stephens L, Williams R, Hawkins P. Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 2005, 5:357-365. 10.1016/j.coph.2005.03.002, 15963759.
11. Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 1995, 15:1135-1139.
12. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000, 6:880-886.
13. Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, Bain J, Jones GE, Vanhaesebroeck B. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 2003, 63:1667-1675.
14. Edling CE, Selvaggi F, Buus R, Maffucci T, Di Sebastiano P, Friess H, Innocenti P, Kocher HM, Falasca M. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 2010, 16:4928-4937. 10.1158/1078-0432.CCR-10-1210, 20876794.
15. Monterrubio M, Mellado M, Carrera AC, Rodriguez-Frade JM. PI3Kgamma activation by CXCL12 regulates tumor cell adhesion and invasion. Biochem Biophys Res Commun 2009, 388:199-204. 10.1016/j.bbrc.2009.07.153, 19660434.
16. Kruiswijk F, Yuniati L, Magliozzi R, Low TY, Lim R, Bolder R, Mohammed S, Proud CG, Heck AJ, Pagano M, Guardavaccaro D. Coupled activation and degradation of eEF2K regulates protein synthesis in response to genotoxic stress. Sci Signal 2012, 5:ra40. 10.1126/scisignal.2002718, 22669845.
17. Brazzatti JA, Klingler-Hoffmann M, Haylock-Jacobs S, Harata-Lee Y, Niu M, Higgins MD, Kochetkova M, Hoffmann P, McColl SR. Differential roles for the p101 and p84 regulatory subunits of PI3Kgamma in tumor growth and metastasis. Oncogene 2012, 31:2350-2361. 10.1038/onc.2011.414, 21996737.
18. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005, 11:936-943.
19. Stephens L, Smrcka A, Cooke FT, Jackson TR, Sternweis PC, Hawkins PT. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell 1994, 77:83-93. 10.1016/0092-8674(94)90237-2, 8156600.
20. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501. 10.1038/nrc839, 12094235.
21. Woo JH, Kim HS. Phosphorylation of eukaryotic elongation factor 2 can be regulated by phosphoinositide 3-kinase in the early stages of myoblast differentiation. Mol Cells 2006, 21:294-301.
22. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 2003, 22:2411-2421. 10.1093/emboj/cdg231, 155989, 12743035.
23. Gschwind A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 2002, 62:6329-6336.
24. Ukegawa JI, Takeuchi Y, Kusayanagi S, Mitamura K. Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells. J Cancer Res Clin Oncol 2003, 129:272-278.
25. Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, Grandis JR. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004, 64:6166-6173. 10.1158/0008-5472.CAN-04-0504, 15342401.
26. Noble PJ, Wilde G, White MR, Pennington SR, Dockray GJ, Varro A. Stimulation of gastrin-CCKB receptor promotes migration of gastric AGS cells via multiple paracrine pathways. Am J Physiol Gastrointest Liver Physiol 2003, 284:G75-84.
27. Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O, Arcaro A. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res 2008, 14:6761-6769. 10.1158/1078-0432.CCR-08-0385, 18980969.
28. Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway. Blood 2007, 110:4243-4252. 10.1182/blood-2006-10-050633, 17827393.
29. Sun H, Kerfant BG, Zhao D, Trivieri MG, Oudit GY, Penninger JM, Backx PH. Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha/PKB signaling. Circ Res 2006, 98:1390-1397. 10.1161/01.RES.0000223321.34482.8c, 16627784.
30. Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007, 21:1921-1930. Epub 2007 Jun 1921, 10.1038/sj.leu.2404813, 17581609.
31. Oak JS, Matheu MP, Parker I, Cahalan MD, Fruman DA. Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. Biochem Soc Trans 2007, 35:1109-1113. 10.1042/BST0351109, 2953540, 17956290.
32. Liu L, Puri KD, Penninger JM, Kubes P. Leukocyte PI3Kgamma and PI3Kdelta have temporally distinct roles for leukocyte recruitment in vivo. Blood 2007, 110:1191-1198. 10.1182/blood-2006-11-060103, 17488877.
33. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000, 287:1049-1053. 10.1126/science.287.5455.1049, 10669418.
34. Ryazanov AG, Rudkin BB, Spirin AS. Regulation of protein synthesis at the elongation stage. New insights into the control of gene expression in eukaryotes. FEBS Lett 1991, 285:170-175. 10.1016/0014-5793(91)80798-8, 1855586.
35. Carlberg U, Nilsson A, Nygard O. Functional properties of phosphorylated elongation factor 2. Eur J Biochem 1990, 191:639-645. 10.1111/j.1432-1033.1990.tb19169.x, 2390990.
36. Vasudevan NT, Mohan ML, Gupta MK, Hussain AK, Naga Prasad SV. Inhibition of protein phosphatase 2A activity by PI3Kgamma regulates beta-adrenergic receptor function. Mol Cell 2011, 41:636-648. 10.1016/j.molcel.2011.02.025, 3063893, 21419339.
37. Everett AD, Stoops TD, Nairn AC, Brautigan D. Angiotensin II regulates phosphorylation of translation elongation factor-2 in cardiac myocytes. Am J Physiol Heart Circ Physiol 2001, 281:H161-167.
38. Ghosh P, Beas AO, Bornheimer SJ, Garcia-Marcos M, Forry EP, Johannson C, Ear J, Jung BH, Cabrera B, Carethers JM, Farquhar MG. A G{alpha}i-GIV molecular complex binds epidermal growth factor receptor and determines whether cells migrate or proliferate. Mol Biol Cell 2010, 21:2338-2354. 10.1091/mbc.E10-01-0028, 2893996, 20462955.
39. Saavedra A, Garcia-Martinez JM, Xifro X, Giralt A, Torres-Peraza JF, Canals JM, Diaz-Hernandez M, Lucas JJ, Alberch J, Perez-Navarro E. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. Cell Death Differ 2010, 17:324-335. 10.1038/cdd.2009.127, 19745829.